[1]刘晓亮.mEOX联合同步放疗对晚期胃癌患者血清肿瘤标记物及生存期的影响[J].医学信息,2020,33(04):112-114.[doi:10.3969/j.issn.1006-1959.2020.04.034]
　LIU Xiao-liang.Effect of mEOX Combined with Concurrent Radiotherapy on Serum Tumor Markers and Survival of Patients with Advanced Gastric Cancer[J].Medical Information,2020,33(04):112-114.[doi:10.3969/j.issn.1006-1959.2020.04.034]
点击复制

mEOX联合同步放疗对晚期胃癌患者血清肿瘤标记物及生存期的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年04期
页码:
112-114
栏目:
临床研究
出版日期:
2020-02-15

文章信息/Info

Title:
Effect of mEOX Combined with Concurrent Radiotherapy on Serum Tumor Markers and Survival of Patients with Advanced Gastric Cancer
文章编号:
1006-1959（2020）04-0112-03
作者:
刘晓亮
（天津河东天铁医院肿瘤内科，河北 涉县 056404）
Author(s):
LIU Xiao-liang
(Department of Oncology,Tianjin Hedong Tiantie Hospital,Shexian 056404,Hebei,China)
关键词:
晚期胃癌; mEOX方案; 同步放疗
Keywords:
Advanced gastric cancer; mEOX regimen; Concurrent radiotherapy
分类号:
R735.2
DOI:
10.3969/j.issn.1006-1959.2020.04.034
文献标志码:
A
摘要:
目的 探讨mEOX方案联合同步放疗治疗晚期胃癌的临床疗效。方法 选取2013年8月~2014年7月我院收治的150例晚期胃癌患者，利用随机数表法分为对照组和观察组，各75例。对照组行mEOX方案化疗，观察组在此基础上联合同步放疗治疗，比较两组临床疗效、血清肿瘤标记物[血清癌胚抗原（CEA）、糖类抗原724（CA724）及糖类抗原199（CA199）]、不良反应发生情况以及随访1、3、5年生存情况。结果 观察组缓解率为92.00%，高于对照组的80.00%，差异有统计学意义（P＜0.05）；治疗后，观察组CEA、CA724及CA199水平低于对照组[（12.83±5.29）ng/ml vs（16.15±6.12）ng/ml]、[（23.45±5.37）U/ml vs（27.92±5.68）U/ml]、[（32.94±9.85）U/ml vs（39.13±10.26）U/ml]，差异有统计学意义（P＜0.05）；观察组QOL评分高于对照组[（50.32±4.46）分vs（46.25±4.37）分]，差异有统计学意义（P＜0.05）；两组不良反应总发生率比较，差异无统计学意义（P＞0.05）；随访1年，两组生存率比较，差异无统计学意义（P＞0.05）；观察组随访3年、5年生存率均高于对照组[（60.00% vs 42.67%）、（25.33% vs 12.00%）]，差异有统计学意义（P＜0.05）；观察组中位生存时间为39个月，长于对照组的34个月，差异有统计学意义（P＜0.05）。结论 mEOX方案联合同步放疗治疗晚期胃癌可有效提升患者缓解率，降低血清肿瘤标记物水平，提升患者生存质量，延长患者生存期。
Abstract:
Objective To explore the clinical efficacy of mEOX regimen combined with concurrent radiotherapy for advanced gastric cancer.Methods A total of 150 patients with advanced gastric cancer treated in our hospital from August 2013 to July 2014 were selected and divided into control group and observation group using the random number table method, with 75 cases each. The control group was treated with mEOX chemotherapy. Based on this, the observation group combined with concurrent radiotherapy. The clinical efficacy, serum tumor markers [serum carcinoembryonic antigen (CEA), carbohydrate antigen 724 (CA724),and carbohydrate antigen 199 (CA199)], occurrence of adverse reactions, and survival at 1, 3, and 5 years of follow-up.Results The remission rate in the observation group was 92.00%, which was higher than 80.00% in the control group,the difference was statistically significant (P<0.05). After treatment, the levels of CEA, CA724 and CA199 in the observation group were lower than the control group [(12.83±5.29) ng/ml vs (16.15±6.12) ng/ml], [(23.45±5.37) U/ml vs (27.92±5.68) U/ml], [(32.94±9.85) U/ml vs (39.13±10.26) U/ml ],the difference was statistically significant (P<0.05); the QOL score of the observation group was higher than the control group [(50.32±4.46) points vs (46.25±4.37) points],the difference was statistically significant (P<0.05); There was no significant difference in the overall incidence of adverse reactions (P>0.05). There was no significant difference in the survival rate between the two groups after 1 year of follow-up (P>0.05). The 3-year and 5-year survival rates of the observation group were higher than those of the control group [(60.00% vs 42.67%),(25.33% vs 12.00%)],the difference was statistically significant (P<0.05); The median survival time in the observation group was 39 months, which was 34 months longer than that in the control group,the difference was statistically significant (P<0.05).Conclusion The mEOX regimen combined with concurrent radiotherapy for advanced gastric cancer can effectively improve the remission rate of patients, reduce the level of serum tumor markers, improve the quality of life of patients, and prolong the survival of patients.

参考文献/References:

[1]刘立杰.尼妥珠单抗联合同步放化疗治疗Her-2阴性局部晚期胃癌疗效观察[J].肿瘤学杂志,2016,22(9):713-717. [2]李建旺,黄春珍,陈琼慧,等.mEOX与FOLFIRI方案二线治疗晚期胃癌疗效对照观察[J].中华肿瘤防治杂志,2016,23(14):952-957. [3]杨学宁,吴一龙.实体瘤治疗疗效评价标准—RECIST[J].循证医学,2004,4(2):85-90. [4]王福立,崔勇,张荣香,等.三维适形放疗同步XELOX方案化疗联合DC-CIK治疗局部进展期胃癌的临床观察[J].医学与哲学(B),2017,38(7):40. [5]周世繁，孙宏新.mEOX与FOLFIRI方案化疗对晚期胃癌患者疗效、血清肿瘤标记物及预后的影响比较[J].山东医药,2018,58(38):52-54. [6]胡媛媛.局部进展期胃癌根治术后三维适形放疗联合S-LOX方案化疗的有效性与安全性分析[J].现代中西医结合杂志,2017,26(33):3703-3705.

相似文献/References:

[1]王国富.贝伐珠单抗联合化学药物治疗晚期胃癌的疗效观察[J].医学信息,2018,31(08):128.[doi:10.3969/j.issn.1006-1959.2018.08.043]
　WANG Guo-fu.Efficacy of Bevacizumab Combined with Chemical Drugs in the Treatment of Advanced Gastric Cancer[J].Medical Information,2018,31(04):128.[doi:10.3969/j.issn.1006-1959.2018.08.043]
[2]王 平,苏志红.参芪扶正注射液辅助治疗晚期胃癌的效果[J].医学信息,2019,32(24):50.[doi:10.3969/j.issn.1006-1959.2019.24.016]
　WANG Ping,SU Zhi-hong.Effect of Shenqi Fuzheng Injection on Adjuvant Treatment of Advanced Gastric Cancer[J].Medical Information,2019,32(04):50.[doi:10.3969/j.issn.1006-1959.2019.24.016]
[3]那文秀.奥沙利铂联合卡培他滨治疗晚期胃癌的疗效[J].医学信息,2020,33(06):144.[doi:10.3969/j.issn.1006-1959.2020.06.046]
　NA Wen-xiu.Efficacy of Oxaliplatin Combined with Capecitabine in the Treatment of Advanced Gastric Cancer[J].Medical Information,2020,33(04):144.[doi:10.3969/j.issn.1006-1959.2020.06.046]

更新日期/Last Update: 2020-02-15